论文部分内容阅读
目的:研究丁苯酞氯化钠注射液(恩必普)联合依达拉奉治疗新发脑梗死的疗效及其对神经功能和CRP水平的影响.方法:选取2015年5月至2017年2月无锡市人民医院收治的64例新发脑梗死患者,按照随机数表法分为试验组和对照组,每组32例.对照组用依达拉奉治疗(30 mg,bid),试验组在对照组基础上联合恩必普注射液(100 mL,bid)进行治疗,所有患者疗程均为10d.比较患者治疗前后CRP水平、神经功能和日常生活能力变化,观察患者的临床疗效和不良反应.结果:治疗后10d,试验组的CRP水平明显低于对照组[(25.32±2.43) mg·L-1 vs (45.11±5.32) mg·L-1],组间比较差异性明显(P＜0.05).试验组的NIHSS评分明显低于对照组[(12.45±2.31)分vs(16.32±3.56)分],BI评分明显高于对照组[(80.32±7.15)分vs (50.87±5.35)分],组间比较差异明显(P＜0.05).试验组总的临床疗效率明显高于对照组[90.62％ (29/32) vs 53.12％ (17/32)] (P ＜0.05).结论:与单独使用依达拉奉相比,恩必普联合依达拉奉治疗新发脑梗死患者能明显改善患者的神经功能和CRP水平.“,”Objective:To investigate the therapeutic effect,nerve function and CRP level of butylphthalide and sodium chloride injection (Enbipu) combined with edaravone on new-onset cerebral infarction.Methods:64 cases of new-onset cerebral infarction patients sequentially collected in Wuxi People's Hospital from May 2015 to February 2017.Those samples were equally split into testing group and control group according to the preset random number.The control group was treated by edaravone (30 mg,bid) for 10 days,while testing group was treated by edaravone (30 mg,bid) combined with Enbipu(100 mL,bid) with the same duration.The CRP level,nerve functions,daily life activities ability changes before and after treatment,the clinical curative effect and adverse reactions were observed.Results:After 10 d treatment,the CRP level of testing group was significantly lower than in the control group [(25.32±2.43) mg·L-1 vs (45.11 ±5.32) mg·L-1,P＜0.05].The NIHSS score of testing group was significantly lower than in the control group [(12.45 ± 2.31) points vs (16.32 ± 3.56) points,P ＜ 0.05],while BI score of testing group was significantly higher than in the control group [(80.32 ±7.15) points vs (50.87 ± 5.35) points,P ＜ 0.05].We also observed that the total curative rate of testing group was significantly higher than the control group [90.62％ (29/32) vs 53.12％ (17/32)] (P ＜ 0.05).Conclusion:The new-onset cerebral infarction patients can benefit from the treatment of Enbipu combined with edaravone,showing better improvement of nerve function and CRP level than edaravone alone.And Enbipu is considered as a safe and effective treatment on new-onset cerebral infarction patients.